Search for: "Healthpoint" Results 1 - 12 of 12
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 May 2012, 1:03 pm
As a result of its false statements, Healthpoint caused Medicaid and Medicare to pay tens of millions of dollars for the unapproved drug. [read post]
1 Apr 2011, 9:56 pm by Ben Vernia
As a result of Healthpoint’s false statements, the United States alleges that Healthpoint caused Medicaid and Medicare to pay tens of millions of dollars for an unapproved drug that was ineligible for reimbursement. [read post]
13 Mar 2013, 9:45 am by Lebowitz & Mzhen
The various complaints related to the settlement alleged that Healthpoint unlawfully marketed Xenaderm without FDA approval. [read post]
28 Jun 2018, 11:41 am by Steven Cohen
  The plaintiff claims that the defendant uses their marks for their business Healthpoint, which is an assessment tool that constructs a personalized plan for health improvements. [read post]
28 Jun 2018, 11:41 am by Steven Cohen
  The plaintiff claims that the defendant uses their marks for their business Healthpoint, which is an assessment tool that constructs a personalized plan for health improvements. [read post]
26 Feb 2013, 11:45 am by Jonathan Rosenfeld
After reading a report about how the manufacturers of Xexaderm, a cream manufactured by and distributed by Healthpoint Ltd. and DFB Pharmaceuticals, were charged with Medicaid fraud by marketing the cream to nursing homes as a cure for bed sore I was (once again) reminding about the lengths facilities will go to attempt to cover up this incredibly prolific example of inferior medical care. [read post]
31 Mar 2011, 6:59 am by DBL Law
  Dietz belongs to the Society of Ohio Healthcare Attorneys and serves on the Board of Directors for HealthPoint Family Care. [read post]
18 Feb 2010, 10:34 am by Beck, et al.
This post is about un-preempted fraud on the FDA claims and how to approach them…. [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]